PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31764002-11 2020 The aggregating effect of VLCV is more sensitive to ticlopidine than to the clopidogrel suggesting the involvement of ADP/P2Y12/PI3K pathway. Ticlopidine 52-63 purinergic receptor P2Y12 Homo sapiens 122-127 33309519-6 2021 The antagonism of platelet P2Y12 receptors by cangrelor, ticagrelor or active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel reduces the ADP-induced platelet aggregation in patients with thrombotic complications of vascular diseases. Ticlopidine 122-133 purinergic receptor P2Y12 Homo sapiens 27-32 30922852-5 2019 The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y12 receptors and reduce thereby platelet aggregation. Ticlopidine 90-101 purinergic receptor P2Y12 Homo sapiens 146-151 22963529-2 2013 The first family of adenosine diphosphate P2Y12 receptors inhibiting drug is represented by thienopyridines and among these ticlopidine was the first approved by Food and Drug Administration; actually its use is discouraged because of its potential side effects (neutropenia, anemia, gastrointestinal distress and thrombotic thrombocytopenic purpura). Ticlopidine 124-135 purinergic receptor P2Y12 Homo sapiens 42-47 24433137-2 2015 Ticlopidine was the first widely used P2Y12 receptor blockers, but clopidogrel has mostly replaced the use of ticlopidine due to its more favorable adverse event profile on bone marrow. Ticlopidine 0-11 purinergic receptor P2Y12 Homo sapiens 38-43 23839753-7 2013 FINDINGS: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (eg, ticlopidine, clopidogrel, prasugrel, ticagrelor) reduces the risk of stent thrombosis and subsequent cardiovascular events post-PCI (number needed to treat, 33-53) and is the current standard of care. Ticlopidine 76-87 purinergic receptor P2Y12 Homo sapiens 55-60 21554368-10 2011 P2Y12 is the same receptor targeted by ticlopidine and clopidogrel, platelet inhibitors used in lieu of aspirin in people at risk for cardiovascular disease; thus, spontaneous bleeding is not expected unless there are other contributing factors. Ticlopidine 39-50 purinergic receptor P2Y12 Homo sapiens 0-5 22906899-3 2012 P2Y(12) inhibitors include ticlopidine (now rarely used), clopidogrel, prasugrel, and ticagrelor. Ticlopidine 27-38 purinergic receptor P2Y12 Homo sapiens 0-7 22360514-2 2012 Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. Ticlopidine 0-11 purinergic receptor P2Y12 Homo sapiens 81-86 22918731-2 2012 Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition. Ticlopidine 74-85 purinergic receptor P2Y12 Homo sapiens 10-15 22918731-2 2012 Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition. Ticlopidine 74-85 purinergic receptor P2Y12 Homo sapiens 184-189 21946108-1 2011 Thienopyridines (ticlopidine, clopidogrel and prasugrel) are pro-drugs that require metabolism to exhibit a critical thiol group in the active form that binds to the P2Y12 receptor to inhibit platelet activation and prevent thrombus formation in vivo. Ticlopidine 17-28 purinergic receptor P2Y12 Homo sapiens 166-171 19334620-1 2009 The key role in platelet aggregation is played by the platelet ADP receptor P2Y12, which is the target for antiaggregant drugs, clopidogrel and ticlopidine. Ticlopidine 144-155 purinergic receptor P2Y12 Homo sapiens 76-81 20831051-2 2010 In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives. Ticlopidine 188-199 purinergic receptor P2Y12 Homo sapiens 130-135 20977463-1 2010 BACKGROUND AND PURPOSE: After conversion to their active forms by the liver, ticlopidine and clopidogrel exert antiplatelet effects through irreversible inhibition of the P2Y12 receptor. Ticlopidine 77-88 purinergic receptor P2Y12 Homo sapiens 171-176 11245644-2 2001 The role of enhanced antiplatelet protection through pretreatment with the platelet ADP-receptor antagonist ticlopidine in preventing both the early and late complications of coronary stenting has not previously been explored. Ticlopidine 108-119 purinergic receptor P2Y12 Homo sapiens 75-96 19463124-3 2009 In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives. Ticlopidine 188-199 purinergic receptor P2Y12 Homo sapiens 130-135 19845526-3 2009 In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives. Ticlopidine 188-199 purinergic receptor P2Y12 Homo sapiens 130-135 20038285-3 2009 In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives. Ticlopidine 188-199 purinergic receptor P2Y12 Homo sapiens 130-135 20038286-3 2009 In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives. Ticlopidine 188-199 purinergic receptor P2Y12 Homo sapiens 130-135 17187456-3 2007 The thienopyridine ticlopidine, an antagonist of the platelet P2Y12 ADP receptor, reduces the incidence of vascular events in patients at risk, but it also has some important drawbacks: a relatively high incidence of toxic effects; delayed onset of action; high inter-individual variability in response. Ticlopidine 19-30 purinergic receptor P2Y12 Homo sapiens 62-67 14717977-1 2004 The P2Y12 ADP receptor is one of the major regulators of platelet activation and the target of antithrombotic thienopyridines (ticlopidine and clopidogrel). Ticlopidine 127-138 purinergic receptor P2Y12 Homo sapiens 4-9 14610915-4 2003 P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). Ticlopidine 139-150 purinergic receptor P2Y12 Homo sapiens 0-5 14610915-4 2003 P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). Ticlopidine 152-158 purinergic receptor P2Y12 Homo sapiens 0-5 11454254-3 2001 The thienopyridines, ticlopidine and clopidogrel, act, via metabolites, on the platelet ADP receptor subtype now designated P2Y(12 )(formerly P(2T), P2T (AC), P2Y (ADP) or P2Y(cyc)) and these agents have proven clinical efficacy. Ticlopidine 21-32 purinergic receptor P2Y12 Homo sapiens 159-168 11454254-3 2001 The thienopyridines, ticlopidine and clopidogrel, act, via metabolites, on the platelet ADP receptor subtype now designated P2Y(12 )(formerly P(2T), P2T (AC), P2Y (ADP) or P2Y(cyc)) and these agents have proven clinical efficacy. Ticlopidine 21-32 purinergic receptor P2Y12 Homo sapiens 172-180 16245416-3 2005 Its mode of action has not been defined, but it appears that metabolites of ticlopidine are antagonists of the platelet ADP receptor. Ticlopidine 76-87 purinergic receptor P2Y12 Homo sapiens 111-132 12913786-4 2003 P2Y(12) is the target of antithrombotic drugs (ticlopidine, clopidogrel), whereas the role of P2Y(1) in thrombosis remains to be fully established. Ticlopidine 47-58 purinergic receptor P2Y12 Homo sapiens 0-7